Skip to content

Gyre Therapeutics, Inc. GYRE Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$11.82M+35.3%$8.74M-25.3%$11.7M-34.6%
$2.62M+5.5%$2.48M+8.5%$2.29M+9.8%$2.08M+24.7%$1.67M+7.7%
$9.23M+29.0%$7.16M+129%$3.13M+41.0%$2.22M+67.1%$1.33M+59.7%
$3.88M
$1.25M+4.7%$1.19M+13.8%$1.05M-2.3%$1.07M-52.8%$2.27M-4.6%
-$4.33M+20.9%-$5.47M+48.9%-$10.7M+46.2%
$23.06M-5.4%$24.38M-2.6%$25.02M+0.2%$24.98M+796%$2.79M+32.6%
$24.54M+20.3%$20.39M+238%-$14.74M+32.1%
$3.07M+1,807%-$180K-106%$2.9M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Gyre Therapeutics, Inc. generate?
Gyre Therapeutics, Inc. (GYRE) generated $9.8M in operating cash flow over the trailing twelve months.
What is Gyre Therapeutics, Inc.'s free cash flow?
After $1.2M of capital expenditures, Gyre Therapeutics, Inc.'s free cash flow was $3.1M over the trailing twelve months, up 142.4% year over year.
Where does Gyre Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.